Recent

% | $
Quotes you view appear here for quick access.

Heron Therapeutics, Inc. Message Board

omkar.bhutani 17 posts  |  Last Activity: May 12, 2015 10:52 PM Member since: Jun 12, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • omkar.bhutani omkar.bhutani May 12, 2015 10:52 PM Flag

    Zacks Rank Rank Change Trend Buy 2
    Zacks Industry Rank 91 / 265 (Top 34%)

    Sentiment: Strong Buy

  • Reply to

    Earnings and Pipeline talk May 30th 8AM

    by oceraous Apr 23, 2015 8:58 AM
    omkar.bhutani omkar.bhutani May 10, 2015 5:24 PM Flag

    Insider continues to buy gurfocus
    Recent Filings Activity
    Symbol Company Insider Position Date Buy/Sell Shares Trade Price ($) Cost ($1000) Price Change
    Since Trade (%) Yield (%) P/E Market Cap ($M) Details
    OCRX Ocera Therapeut... Patni Rajiv Chief Development Officer 2015-05-07 Buy 5,050 $3.97 20 -3.02 0.00 0.00 76.027 Link
    OCRX Ocera Therapeut... Grais Linda S President and CEO
    (Click for the stocks that their CEOs have bought) 2015-05-06 Buy 30,000 $3.73 111.9 3.22 0.00 0.00 76.027 Link
    OCRX Ocera Therapeut... Byrnes Michael CFO and Treasurer 2015-05-06 Buy 2,500 $3.61 9 6.65 0.00 0.00 76.027 Link
    OCRX Ocera Therapeut... Aggarwal Gaurav Chief Business Officer 2015-05-06 Buy 7,500 $3.62 27.2 6.35 0.00 0.00 76.027 Link
    OCRX Ocera Therapeut... Byrnes Michael VP, Finance & Treasurer 2014-10-01 Buy 2,000 $4.81 9.6 -19.96 0.00 0.00 76.027 Link
    OCRX Ocera Therapeut... TETLOW SHARON Acting CFO & Treasurer 2014-07-11 Buy 3,000 $5.83 17.5 -33.96 0.00 0.00 76.027 Link
    OCRX Ocera Therapeut... Grais Linda S President and CEO 2014-07-11 Buy 10,0

    Sentiment: Strong Buy

  • Reply to

    Earnings and Pipeline talk May 30th 8AM

    by oceraous Apr 23, 2015 8:58 AM
    omkar.bhutani omkar.bhutani May 4, 2015 10:27 PM Flag

    Ocera Therapeutics, Inc. (OCRX) + Follow
    $3.42 +2.09%
    May 04, 4:00 PM EST
    Analysts 4
    Positive 80%
    Median target $16 (367% upside) flashrating

    Sentiment: Strong Buy

  • omkar.bhutani omkar.bhutani May 4, 2015 10:25 PM Flag

    Synta Pharmaceuticals Corp. (SNTA) + Follow
    $2.42 +1.26%
    May 04, 4:00 PM EST
    Analysts 10
    Positive 70%
    Median target $9 (271% upside) flashrating

    Sentiment: Strong Buy

  • Reply to

    Earnings and Pipeline talk May 30th 8AM

    by oceraous Apr 23, 2015 8:58 AM
    omkar.bhutani omkar.bhutani May 1, 2015 11:41 PM Flag

    Ocera Therapeutics Raised to “Strong-Buy” at Zacks (OCRX)
    Posted by Seth Barnet on Apr 30th, 2015 Share on StockTwits

    Ocera Therapeutics logoOcera Therapeutics (NASDAQ:OCRX) was upgraded by Zacks from a “buy” rating to a “strong-buy” rating in a report issued on Thursday. The firm currently has a $5.00 target price on the stock. Zacks‘s price objective points to a potential upside of 47.93% from the company’s current price.

    Zacks’ analyst wrote, “Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera Therapeutics, Inc., formerly known as Tranzyme, Inc., is based in San Diego, California.

    Sentiment: Strong Buy

  • Reply to

    No insiders have sold.

    by trollingtrolls Apr 27, 2015 6:17 PM
    omkar.bhutani omkar.bhutani Apr 27, 2015 9:23 PM Flag

    Flashrating

    Synta Pharmaceuticals Corp. (SNTA)
    Median target price: $7.75 (218% upside)
    Positive ratings 70% of 10 analysts

    Latest: Roth Capital | buy | $13 | 04/27

    View all analyst ratings for APT »

    Sentiment: Strong Buy

  • Reply to

    FBR coverage

    by all_hail_k Apr 20, 2015 6:03 PM
    omkar.bhutani omkar.bhutani Apr 26, 2015 12:34 AM Flag

    SNTA has been the subject of a number of other recent research reports. Analysts at Canaccord Genuity initiated coverage on shares of Synta Pharmaceuticals Corp. in a research note on Friday. They set an “outperform” rating on the stock. Analysts at MLV & Co. set a $6.50 price target on shares of Synta Pharmaceuticals Corp. and gave the company a “buy” rating in a research note on Friday, March 13th. The company presently has a consensus rating of “Buy” and an average target price of $11.83.

    Sentiment: Strong Buy

  • omkar.bhutani omkar.bhutani Apr 12, 2015 10:50 PM Flag

    Synta Pharmaceuticals Corp. Receives New Coverage from Analysts at Canaccord Genuity (SNTA)
    April 12th, 2015 - 0 comments - Filed Under - by Jennifer Langley
    Stock analysts at Canaccord Genuity initiated coverage on shares of Synta Pharmaceuticals Corp. (NASDAQ:SNTA) in a report issued on Friday. The firm set an “outperform” rating on the stock.

    Sentiment: Strong Buy

  • Reply to

    Targets remain the same

    by bkftransit Mar 20, 2015 12:02 PM
    omkar.bhutani omkar.bhutani Mar 22, 2015 10:36 PM Flag

    Premium Research for SNTA
    Zacks Rank [?] Buy 2
    Zacks Industry Rank [?] 77 / 265 (Top 29%)

    Synta Pharmaceuticals Corp. (SNTA)
    + Follow
    Median target: $9 (262% upside)
    Positive ratings: 57% of 7
    $2.48 +0.07 (+2.90%)
    Mar 20, 4:00 PM EST view details
    7 days 30 days 90 days 1 year

    Date
    Analyst
    Latest Rating
    Latest Target
    03/13
    MLV & Co
    buy
    $6.5
    02/06
    Roth Capital
    buy
    $20
    08/08
    JMP Securities
    market outperform
    $9
    FLASHRATING RESEARCH

    Sentiment: Strong Buy

  • Reply to

    Huge potential catalyst!!!!!

    by eyegeewhiz Mar 13, 2015 12:47 PM
    omkar.bhutani omkar.bhutani Mar 15, 2015 10:27 PM Flag

    n a research note issued this morning, MLV analyst Arlinda Lee reiterated a Buy rating on Synta Pharmaceuticals Corp. (NASDAQ:SNTA) with a $6.50 price target, after the company reported fourth-quarter results and held a conference call yesterday morning to provide a corporate update.

    Lee noted, “We think first interim analysis from the Phase 3 GALAXY-2 trial of docetaxel +/- ganetespib in 2nd-line non-small cell lung cancer (NSCLC) in 2H15 will be Synta’s most impactful catalyst this year. Given the encouraging Phase 2 GALAXY-1 final dataset, we are cautiously optimistic for a positive interim readout.”

    Sentiment: Strong Buy

  • omkar.bhutani omkar.bhutani Mar 10, 2015 10:27 PM Flag

    Civeo Corp (CVEO) FLASHRATING
    + Follow
    Median target: $6 (78% upside)f
    Growth Value:
    $ 7.25

    Terminal Value:
    $ 4.55

    = Fair Value:
    $ 11.8

    Result may not be accurate due to the low predictability of business
    Margin Of Safety:
    71% GURUFOCUS

    Sentiment: Strong Buy

  • Reply to

    ???!!! upside

    by ronnietal Mar 9, 2015 11:13 AM
    omkar.bhutani omkar.bhutani Mar 10, 2015 10:24 PM Flag

    Premium Research for OCRX
    Zacks Rank [?] Rank Change Trend Hold 3
    Zacks Industry Rank 91 / 265 (Top 34%)

    Ocera Therapeutics, Inc. (OCRX)
    + Follow
    Median target: $16 (273% upside)
    Positive ratings: 80% of 5
    Flashrating

    Sentiment: Strong Buy

  • Reply to

    all buyers from here

    by dhamel28 Mar 5, 2015 3:40 PM
    omkar.bhutani omkar.bhutani Mar 10, 2015 10:21 PM Flag

    Premium Research for SNTA
    Zacks Rank [?] Rank Change Trend Buy 2
    Zacks Industry Rank 91 / 265 (Top 34%)

    Synta Pharmaceuticals Corp. (SNTA)
    + Follow
    Median target: $9 (275% upside)
    Positive ratings: 57% of 7
    $2.40 -0.04 (-1.64%)
    Mar 10, 4:00 PM EST view details
    7 days 30 days 90 days 1 year

    Date
    Analyst
    Latest Rating
    Latest Target
    02/06
    Roth Capital
    buy
    $20
    08/08
    JMP Securities
    market outperform
    $9
    flashrating

    Sentiment: Strong Buy

  • omkar.bhutani omkar.bhutani Mar 4, 2015 10:38 PM Flag

    MOST UNDERVALUED
    Growth Value:
    $ 7.25

    Terminal Value:
    $ 4.55

    = Fair Value:
    $ 11.8

    Result may not be accurate due to the low predictability of business
    Margin Of Safety:
    69%
    GURUFOCUS

    Sentiment: Strong Buy

  • Reply to

    Buy More

    by europeans4 Feb 19, 2015 4:53 AM
    omkar.bhutani omkar.bhutani Mar 2, 2015 9:40 PM Flag

    Average Recommendation: Buy Average Target Price: 17.00
    Number of Ratings: 3 MARKET WATCH

    Sentiment: Strong Buy

  • omkar.bhutani omkar.bhutani Mar 2, 2015 9:27 PM Flag

    Median target: $9 (278% upside)
    Positive ratings: 57% of 7
    $2.38 (-0.83%)
    Mar 02, 4:00 PM EST
    7 days 30 days 90 days 1 year

    Date
    Analyst
    Latest Rating
    Latest Target
    02/06
    Roth Capital
    buy
    $20
    08/08
    JMP Securities
    market outperform
    $9
    05/12
    MLV & Co
    buy
    $6.5
    FLASHRATING
    Premium Research for SNTA
    Zacks Rank [?] Rank Change Trend Buy 2
    Zacks Industry Rank 84 / 265 (Top 32%)

    Sentiment: Strong Buy

  • omkar.bhutani omkar.bhutani Feb 25, 2015 8:37 PM Flag

    Price/Book 15.89
    Price / Sales 7.94
    Zack research

    Sentiment: Strong Buy

APPAD
12.300.00(0.00%)Jan 22 3:59 PMEST